Status:

COMPLETED

Olmesartan as an add-on to Amlodipine in Hypertension

Lead Sponsor:

Sankyo Pharma Gmbh

Conditions:

Essential Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone

Eligibility Criteria

Inclusion

  • Without antihypertensive pre-treatment mean seated BP greater than 160/100 mmHg
  • Pre-treatment with amlodipine 5 or 10 mg: mean seated BP greater than or equal to 140/90 mmHg

Exclusion

  • Secondary hypertension
  • Any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

End Date :

August 1 2007

Estimated Enrollment :

632 Patients enrolled

Trial Details

Trial ID

NCT00220233

Start Date

April 1 2005

End Date

August 1 2007

Last Update

December 24 2018

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Leipzig, Germany

2

Sinsheim, Germany

3

Tann, Germany

4

Weinheim, Germany

Olmesartan as an add-on to Amlodipine in Hypertension | DecenTrialz